A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01‐001). Issue 5 (28th February 2023)

• Record Type: Journal Article
• Authors: Yildirim, Halil Cumhur; Kupik, Gulnihan Eren; Mustafayev, Teuta Zoto; Berber, Tanju; Yavuz, Berrin; Cetinayak, Oguz; Akagunduz, Ozlem; Bıcakcı, Beyhan Ceylaner; Arslan, Suheyla Aytac; Soykut, Ela Delikgoz; Gundog, Mete; Figen, Metin; Teke, Fatma; Canyilmaz, Emine; Birgi, Sumerya Duru; Duzova, Mursel; İgdem, Sefik; Abakay, Candan Demiroz; Atasoy, Beste; Kaydihan, Nuri; Parvizi, Murtaza; Uslu, Gonca Hanedan; Saginc, Halil; Akman, Fadime; Ozyar, Enis
• Is Part Of: Head & neck. Volume 45:Issue 5(2023)
• Page Start: 1194
• Page End: 1205
• Publication Date: 2023-02-28
• Subjects: chemoradiotherapy -- EBV‐DNA -- intensity‐modulated radiotherapy -- nasopharyngeal carcinoma -- nonendemic; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.27333
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: We aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. Methods: In a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. Results: Median age was 48 (9–83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III‐IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6–78) months follow‐up, 8.2% locoregional and 8% distant relapse were observed. Three‐year overall survival was 89.5% and was lower in patients with age ≥50, male sex, keratinizing histology, T4, N3 and advanced stage (III‐IVA). Conclusions: Patients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower.